Jazz Q2 revenue >$1B record; key drugs up 13-22%; guides EPS higher

Jazz Pharmaceuticals plc

2024-Q2 EPS reported $2.35 revenue$1,925,808,000

Xywav sales +13%, Epidiolex +22%, Rylaze +6% YoY; oncology revenue +10% YoY.
Zanidatamab granted Priority Review; PDUFA Nov 29, 2024 for 2L BTC.
Narrowed 2024 total revenue guidance to $4.0-$4.1B; lowered oncology outlook to $1.10-$1.15B.
GAAP EPS guidance raised to $6.00-$8.00; non-GAAP EPS to $19.20-$20.30.
GAAP net income affirmed $385-$530M; non-GAAP adjusted net income $1.275-$1.350B.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.